Recent Analysts’ Ratings Updates for ELEKTA UNSP ADR EACH REPR 1 (EKTAY)

Recent Analysts’ Ratings Updates for ELEKTA UNSP ADR EACH REPR 1 (EKTAY) December 21st, 2015 – By Maddie Sorensen – 0 comments ELEKTA UNSP ADR EACH REPR 1 (OTCMKTS: EKTAY) has recently received a number of price target changes and ratings updates: 12/18/2015 – ELEKTA UNSP ADR EACH REPR 1 was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Elekta AB is a human care company engaged in developing and selling clinical solutions for the treatment of cancer and neurological diseases. It develops tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. The Company’s offering is divided into five areas: Neuroscience, Oncology, Software, Brachytherapy and…


Link to Full Article: Recent Analysts’ Ratings Updates for ELEKTA UNSP ADR EACH REPR 1 (EKTAY)